Calcimimetics in CKD—results from recent clinical studies

Schlieper, Georg; Floege, Jürgen

doi:10.1007/s00467-008-0900-4

Cited by 10 publications

(7 citation statements)

References 33 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In secondary HPT, hypocalcaemia and phosphate retention stimulate the parathyroid glands, resulting in parathyroid hyperplasia and increased PTH concentrations. Secondary HPT is one of the first metabolic complications of chronic kidney disease (CKD) and has been associated with untoward effects such as renal bone disease, increased cardiovascular morbidity and death from (cardio)vascular calcifications. Successful kidney transplantation can reverse secondary HPT.…”

Section: Introductionmentioning

confidence: 99%

Systematic review of surgical and medical treatment for tertiary hyperparathyroidism

Dulfer

Franssen

Hesselink

et al. 2017

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Systematic review of surgical and medical treatment for tertiary hyperparathyroidism

Dulfer

Franssen

Hesselink

et al. 2017

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…Several different authors proposed proof showing that control of the calcium intake or lowering parathyroid hormone levels, in particular with the help of calcimimetic cinacalcet, results in a reduction in calcium content in the vasculature of individuals with end-stage renal disease. Eventually, this did not result in a decrease in atherosclerotic cardiovascular disease in patients with end-stage renal disease [ 81 ].…”

Section: Pathophysiologic Considerations Of Ascvd In Ckdmentioning

confidence: 99%

Atherosclerosis Specific Features in Chronic Kidney Disease (CKD)

et al. 2022

View full text Add to dashboard Cite

Atherosclerosis is the major cause of cardiovascular disease, leading to a high mortality rate worldwide. Several risk factors are known to favor atherogenesis, among which are high blood pressure, smoking, diabetes mellitus, and others. Chronic kidney disease is another serious health problem associated with significant health care costs, morbidity, and mortality. Chronic kidney disease shares several risk factors with atherosclerosis and cardiovascular diseases, such as hypertension and diabetes mellitus. Additional risk factors for cardiovascular disease development should be considered in patients with chronic kidney disease. Interestingly, patients suffering from chronic kidney disease are more prone to cardiovascular problems than the general population. Moreover, chronic kidney disease is characterized by an increased atherosclerotic burden from the very early stages. The purpose of this review was to summarize data on atherosclerosis in chronic kidney disease, highlighting the specific features of the disease combination.

show abstract

“…It is found that secondary hyperparathyroidism frequently develops during stages 3 and 4 of CKD. 7 Treatment options aimed at suppressing iPTH currently include dietary P restrictions, P binding, and supplementation with active Vit D and Ca. Dialysis provides additional means of P removal as well as helping to control acid–base balance and removes uremic toxins detrimental to bone health.…”

Section: Introductionmentioning

confidence: 99%

“… 18 Cinacalcet shifts the set point for Ca-regulated iPTH secretion to the left leading to a reduction in iPTH secretion. 7 …”

Section: Introductionmentioning

confidence: 99%

Cinacalcet in Pediatric and Adolescent Chronic Kidney Disease

et al. 2015

View full text Add to dashboard Cite

Cinacalcet, a calcimimetic drug, has been shown to be efficacious in adult chronic kidney disease (CKD) patients; however, it was not fully studied in pediatric CKD patients. We aimed at assessing the effect of cinacalcet on intact parathyroid hormone (iPTH) secretion in children with CKD-4/5 with iPTH consistently ≥ 300 pg/mL refractory to conventional treatment.This is a prospective cohort analysis of 28 children with uncontrolled hyper-parathyroidism secondary to stage 4 and 5 CKD admitted to a tertiary center during the period from April 2012 to April 2014.Twenty-eight patients with CKD-4/5 were assessed prospectively regarding bone biochemistry, renal ultrasonography, serum iPTH level, and medications. Patients were classified into 3 groups: group 1, 6 patients with CKD-4 on supplemental and supportive therapy; group 2, 6 patients with CKD-5 on hemodialysis and; group 3, 16 patients with CKD-5 on automated peritoneal dialysis. Patients were between the ages of 9 months and 18 years on commencing cinacalcet at doses of 0.5 to 1.5 mg/kg.All patients showed at least a 60% reduction in iPTH (60%–97%). Highly significant reduction in iPTH and serum alkaline phosphatase levels was detected post-cinacalcet. The serum calcium (Ca), phosphate (P), and Ca × P product were unaffected. Treatment was well tolerated with no hypophosphatemia, hypocalcemia, or other adverse effects almost in all patients.Cinacalcet use was proven safe for all pediatric and adolescent patients with CKD-4/5 during the study period, and at the same time most of the patients reached the suggested iPTH target values

show abstract

Calcimimetics in CKD—results from recent clinical studies

Cited by 10 publications

References 33 publications

Systematic review of surgical and medical treatment for tertiary hyperparathyroidism

Systematic review of surgical and medical treatment for tertiary hyperparathyroidism

Atherosclerosis Specific Features in Chronic Kidney Disease (CKD)

Cinacalcet in Pediatric and Adolescent Chronic Kidney Disease

Contact Info

Product

Resources

About